BrightGene Bio-Medical Technology Co Ltd
SSE:688166

Watchlist Manager
BrightGene Bio-Medical Technology Co Ltd Logo
BrightGene Bio-Medical Technology Co Ltd
SSE:688166
Watchlist
Price: 32 CNY 3.59% Market Closed
Market Cap: 13.5B CNY
Have any thoughts about
BrightGene Bio-Medical Technology Co Ltd?
Write Note

BrightGene Bio-Medical Technology Co Ltd
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BrightGene Bio-Medical Technology Co Ltd
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
BrightGene Bio-Medical Technology Co Ltd
SSE:688166
Free Cash Flow
-ÂĄ209m
CAGR 3-Years
-1%
CAGR 5-Years
-34%
CAGR 10-Years
N/A
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Free Cash Flow
ÂĄ2.9B
CAGR 3-Years
44%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Free Cash Flow
ÂĄ1.1B
CAGR 3-Years
12%
CAGR 5-Years
-6%
CAGR 10-Years
29%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Free Cash Flow
ÂĄ6.3B
CAGR 3-Years
64%
CAGR 5-Years
17%
CAGR 10-Years
17%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Free Cash Flow
ÂĄ4B
CAGR 3-Years
-2%
CAGR 5-Years
N/A
CAGR 10-Years
14%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Free Cash Flow
-ÂĄ697.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

BrightGene Bio-Medical Technology Co Ltd
Glance View

Market Cap
13.5B CNY
Industry
Pharmaceuticals

BrightGene Bio-Medical Technology Co., Ltd. engages in the research, development, and manufacturing of biopharmaceuticals, medicines as well as special generic active pharmaceutical ingredients and finished dosage forms. The company is headquartered in Suzhou, Jiangsu and currently employs 910 full-time employees. The company went IPO on 2019-11-08. The firm's main products include antifungal active pharmaceutical ingredients (APIs), antiviral APIs, immunosuppressive APIs, and other APIs and preparations. The firm's generic drugs mainly include entecavir, caspofungin, micafungin, posaconazole, everolimus and fondaparinux sodium. The firm mainly conducts its businesses in domestic and overseas markets.

Intrinsic Value
22.57 CNY
Overvaluation 29%
Intrinsic Value
Price

See Also

What is BrightGene Bio-Medical Technology Co Ltd's Free Cash Flow?
Free Cash Flow
-209m CNY

Based on the financial report for Dec 31, 2023, BrightGene Bio-Medical Technology Co Ltd's Free Cash Flow amounts to -209m CNY.

What is BrightGene Bio-Medical Technology Co Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-34%

Over the last year, the Free Cash Flow growth was 50%. The average annual Free Cash Flow growth rates for BrightGene Bio-Medical Technology Co Ltd have been -1% over the past three years , -34% over the past five years .

Back to Top